"Weight Loss Drugs: Disruptive Power and New Uses Drive Low Valuations for Distributors"

The rise of diabetes and weight loss drugs like Ozempic is not only impacting the pharmaceutical industry but also other sectors such as retailers and food companies. GLP-1 drugs, which regulate appetite and induce weight loss, have already driven significant profits for companies like Novo Nordisk and Eli Lilly. The market potential for weight loss drugs is enormous, with millions of obese individuals worldwide. These drugs could also have potential applications in treating cardiovascular disease, addiction, and Alzheimer's. The disruption caused by weight loss drugs is affecting diet companies, retailers, and even bariatric surgery. However, experts caution that drugs alone cannot eliminate the risks of a poor diet, and other approaches to fighting obesity are still necessary.